Wire Stories
First Patient Enrolled in AVITA Therapeutic�s Pivotal Study Evaluating the RECELL System for Repigmentation of Stable Vitiligo
VALENCIA, Calif. & MELBOURNE, Australia–(BUSINESS WIRE)–AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology...